貝因美(002570.SZ):經銷商持股計劃屆滿 受託人已對信託計劃變現清算
格隆匯11月21日丨貝因美(002570.SZ)披露經銷商持股計劃屆滿暨實施情況,經銷商持股計劃對應產品為“北方信託——貝因美經銷商持股計劃2號集合資金信託計劃”(“信託計劃”),信託計劃於2018年11月13日正式成立,募集信託資金合計1500萬元,存續期限1年。該信託計劃持有公司股票288.26萬股,佔公司總股本的0.2819%。
近日,公司收到北方國際信託股份有限公司發出的《北方信託——貝因美經銷商持股計劃2號集合資金信託計劃清算報告》,信託計劃已於2019年11月13日屆滿,信託計劃受託人已對信託計劃變現清算。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.